Jenneke Keizer-Garritsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jenneke Keizer-Garritsen has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alain J. van Gool
Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center
2 shared publications - Esther Willems
Radboud Institute of Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, the Netherlands
2 shared publications - Jolein Gloerich
Department of Human Genetics , Translational Metabolic Laboratory , Radboud University Medical Center , Nijmegen 6525 GA 10 , the Netherlands , radboudumc.nl
2 shared publications - Marien I. de Jonge
Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands
2 shared publications - Acar
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
1 shared publication - Anneke I. Den Hollander
Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 25 November 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (12) , 1256
Semi-Quantitative Multiplex Profiling of the Complement System Identifies Associations of Complement Proteins with Genetic Variants and Metabolites in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. The complement system has been identified as one of the main AMD disease pathways. We performed a comprehensive expression analysis of 32 complement proteins in plasma samples of 255 AMD patients and 221 control individuals using mass spectrometry-based semi-quantitative multiplex profiling. We detected significant associations of complement protein levels with age, sex and body-mass index (BMI), and potential associations of C-reactive protein, factor H related-2 (FHR-2) and collectin-11 with AMD. In addition, we confirmed previously described associations and identified new associations of AMD variants with complement levels. New associations include increased C4 levels for rs181705462 at the C2/CFB locus, decreased vitronectin (VTN) levels for rs11080055 at the TMEM97/VTN locus and decreased factor I levels for rs10033900 at the CFI locus. Finally, we detected significant associations between AMD-associated metabolites and complement proteins in plasma. The most significant complement-metabolite associations included increased high density lipoprotein (HDL) subparticle levels with decreased C3, factor H (FH) and VTN levels. The results of our study indicate that demographic factors, genetic variants and circulating metabolites are associated with complement protein components. We suggest that these factors should be considered to design personalized treatment approaches and to increase the success of clinical trials targeting the complement system.
- 25 November 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (12) , 1256
Open AccessSemi-Quantitative Multiplex Profiling of the Complement System Identifies Associations of Complement Proteins with Genetic Variants and Metabolites in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. The complement system has been identified as one of the main AMD disease pathways. We performed a comprehensive expression analysis of 32 complement proteins in plasma samples of 255 AMD patients and 221 control individuals using mass spectrometry-based semi-quantitative multiplex profiling. We detected significant associations of complement protein levels with age, sex and body-mass index (BMI), and potential associations of C-reactive protein, factor H related-2 (FHR-2) and collectin-11 with AMD. In addition, we confirmed previously described associations and identified new associations of AMD variants with complement levels. New associations include increased C4 levels for rs181705462 at the C2/CFB locus, decreased vitronectin (VTN) levels for rs11080055 at the TMEM97/VTN locus and decreased factor I levels for rs10033900 at the CFI locus. Finally, we detected significant associations between AMD-associated metabolites and complement proteins in plasma. The most significant complement-metabolite associations included increased high density lipoprotein (HDL) subparticle levels with decreased C3, factor H (FH) and VTN levels. The results of our study indicate that demographic factors, genetic variants and circulating metabolites are associated with complement protein components. We suggest that these factors should be considered to design personalized treatment approaches and to increase the success of clinical trials targeting the complement system.
- Open Access
- 1 July 2019
- Published by Elsevier in EBioMedicine
- Vol. 45, 303-313
Biosynthetic homeostasis and resilience of the complement system in health and infectious disease
- 1 July 2019
- Published by Elsevier in EBioMedicine
- Vol. 45, 303-313
Open AccessBiosynthetic homeostasis and resilience of the complement system in health and infectious disease
- 1 January 2003
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 40 (1) , 86-93
Measurement of thiopurine S -methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children
Background: Monitoring 6-thiopurine S-methyltransferase (TPMT; EC 2.1.1.67) activity is especially important when patients are treated with 6-thiopurine drugs, since severe bone marrow toxicity may be induced if patients have deficient TPMT activity. Methods: We have developed a method based on high-performance liquid chromatography (HPLC) for the measurement of TPMT activity in various cell types: erythrocytes (RBC), human peripheral blood mononuclear cells (pMNC) and human malignant lymphoblasts (Molt-F4). The enzymatic activity is measured by the amount of 6-methylmercaptopurine formed, using 6-mercaptopurine (6MP) as substrate and S-adenosylmethionine as co-substrate. Results: The K m values calculated for 6MP were 0·54 (RBC), 0·85 (pMNC) and 0·65 (Molt-F4 cells) mmol/L. The K m values for S-adenosylmethionine were 11·9 (RBC), 16·4 (pMNC) and 6·65 (Molt-F4 cells) µmol/L. The assay variation was 8·2-17%. TPMT activity was determined in a control group of 103 children and young adults (44 female, 59 male). The values observed were (mean ± standard deviation): female children and young adults, 15·1 ± 4·8 pmol/10 7 cells per h ( n = 44); male children and young adults, 15·8 ± 6·4 pmol/10 7 cells per h ( n = 59). No gender or age differences were found. Conclusion: The HPLC-based method enables the rapid screening of TPMT activities in large groups of patients treated with 6-thiopurines.
- 1 January 2003
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 40 (1) , 86-93
Measurement of thiopurine S -methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children
Background: Monitoring 6-thiopurine S-methyltransferase (TPMT; EC 2.1.1.67) activity is especially important when patients are treated with 6-thiopurine drugs, since severe bone marrow toxicity may be induced if patients have deficient TPMT activity. Methods: We have developed a method based on high-performance liquid chromatography (HPLC) for the measurement of TPMT activity in various cell types: erythrocytes (RBC), human peripheral blood mononuclear cells (pMNC) and human malignant lymphoblasts (Molt-F4). The enzymatic activity is measured by the amount of 6-methylmercaptopurine formed, using 6-mercaptopurine (6MP) as substrate and S-adenosylmethionine as co-substrate. Results: The K m values calculated for 6MP were 0·54 (RBC), 0·85 (pMNC) and 0·65 (Molt-F4 cells) mmol/L. The K m values for S-adenosylmethionine were 11·9 (RBC), 16·4 (pMNC) and 6·65 (Molt-F4 cells) µmol/L. The assay variation was 8·2-17%. TPMT activity was determined in a control group of 103 children and young adults (44 female, 59 male). The values observed were (mean ± standard deviation): female children and young adults, 15·1 ± 4·8 pmol/10 7 cells per h ( n = 44); male children and young adults, 15·8 ± 6·4 pmol/10 7 cells per h ( n = 59). No gender or age differences were found. Conclusion: The HPLC-based method enables the rapid screening of TPMT activities in large groups of patients treated with 6-thiopurines.